Published in OBGYN and Reproduction Week, November 3rd, 2008
The clinical poster highlights results from the multi-center Phase 2 recurrent ovarian cancer trial in France where the level of anti-cancer activity of ProLindac in a heavily-pretreated patient population compares favorably to previously published results of single agent oxaliplatin in patients that had less pretreatment. These promising...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of OBGYN and Reproduction Week